Searchable abstracts of presentations at key conferences in endocrinology

ea0085oc6.5 | Oral Communications 6 | BSPED2022

Bone mineralisation as assessed by bone health index in children with congenital adrenal hyperplasia

Francesca Roberts Hannah , Chinoy Amish , Padidela Raja

Background: 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is characterised by cortisol deficiency, androgen excess, varying degrees of virilisation and salt-wasting. CAH management involves replacement therapy with hydrocortisone, and, often, fludrocortisone. High levels of androgens cause the advancement of bone age (BA) with the potential to increase bone mineralisation. Hydrocortisone therapy on the contrary can contribute to reducing bone mineralisation. P...

ea0085p82 | Pituitary and Growth 2 | BSPED2022

Glucagon tolerance tests in a tertiary paediatric centre: an evidence-base for protocol refinement

Farley Hannah , Gilbert Jennifer , Daskas Nikolaos

Background: The glucagon tolerance test (GTT) is used to diagnose growth hormone deficiency (GHD) in younger children or in patients where the insulin tolerance test is contraindicated. We assessed GTTs carried out over five years in a tertiary paediatric centre to assess growth hormone (GH) and cortisol axes. The aim was to assess at which time points the GH peak was observed, and assess whether any predictive value is gained from demographics or IGF-1....

ea0086p96 | Neuroendocrinology and Pituitary | SFEBES2022

A case of chronic hyponatremia secondary to SIADH treated with low dose Tolvaptan to prevent recurrent hospital admission and proven cost effective

Ahsan Masato , Smurthwaite Hannah , Mani Hamidreza

Introduction: Tolvaptan, a selective vasopressin 2 receptor antagonist is proving beneficial in managing hyponatremia secondary to SIADH.Case report: A 75-year-old male with history of traumatic SAH developed hyponatremia secondary to SIADH. He had multiple admissions with symptomatic hyponatremia. His sodium level kept dropping despite putting on fluid restriction and trial of sodium chloride tablets. He was started on Tolvaptan 7.5 once weekly initiall...

ea0066oc6.4 | Oral Communications 6 | BSPED2019

Exam preparedness in students with type 1 diabetes and their schools – a quality improvement study

Yard Hannah , Bretland Corrina , Shetty Ambika

Introduction: Type 1 diabetes (T1D) is a lifelong condition affecting over 29 000 children in the United Kingdom, the majority of whom are in full time education. Both hypoglycaemia and hyperglycaemia have been shown to impact the young person’s overall school performance and learning capacity. During exams, children and young people (CYP) with T1D have the additional stress of managing their diabetes appropriately, and therefore require special provisions. Currently, the...

ea0049ep575 | Diabetes complications | ECE2017

Management of diabetic ketoacidosis in haemodialysis patient

Hendra Heidy , Stacey Hannah , Abeygunasekara Sumith

Introduction: Diabetes mellitus is the commonest cause of chronic kidney disease leading to end-stage renal failure (ESRF). Fluid replacement is one of the cornerstone treatments of DKA, however anuric dialysis patients are at risk of fluid overload. Information for managing DKA in haemodialysis patients is relatively sparse.Case report: A 76-year-old gentleman with type 1 diabetes was admitted with drowsiness. He has twice weekly dialysis and on 700 ml/...

ea0044ep41 | (1) | SFEBES2016

A rare case of Diabetic ketoacidosis (DKA) in a patient with genetically confirmed maturity onset diabetes of young (MODY)

Mcquade Hannah , Ahmad Sajjad , Stephen Stanaway

Maturity Onset Diabetes of the Young (MODY) accounts for upto 2% of all patients with diabetes. Hepatocyte Nuclear Factor 1 alpha (HNF1-A) MODY is the most common subtype accounting for 30–70% of all MODY cases. Typically, it presents in young adults below the age of 45, frequently < 25 with autosomal dominant family history of diabetes, absence of autoimmune markers and insulin resistance and c-peptide positivity.DKA is a rare complication of M...

ea0044ep94 | (1) | SFEBES2016

A case of severe hypercalcaemia caused by hyperthyroidism with concomitant adrenal insufficiency

Sabin Jodie , Coakley Hannah , Evans Alison

Hypercalcaemia is a recognised feature of hyperthyroidism due to accelerated bone turnover caused by thyroid hormone. When present, it is generally mild, usually with levels < 3.00 mmol/l. We present a case of a 19 year old male with thyrotoxicosis, who had severe hypercalcaemia and was also found to have possible co-existent adrenal insufficiency at the same time.He presented with a 4 month history of weight loss, anxiety, tremors and palpitations. ...

ea0038p175 | Neoplasia, cancer and late effects | SFEBES2015

Confusion in a patient with carcinoid syndrome

Aarella Vikram , Dix Hannah , Lee Stuart

A 64 year old lady was admitted with a 2 day history of feeling generally unwell. Her relatives also reported new onset confusion over these 2 days. Her bloods showed raised inflammatory markers (CRP 110.3 mg/l, WCC 18.2×109/l) hypoalbuminemia (17 g/l), bilirubinemia (55 μmol/l) and a raised alkaline phosphatase (917 IU/l). She had recently been diagnosed with carcinoid syndrome; primary tumour situated in the terminal ileum with liver metastasis and had b...

ea0031p312 | Pituitary | SFEBES2013

Metformin treatment of PCOS: St George's Hospital Endocrine Unit Clinical Experience

Walton Hannah , Mason Helen , Bano Gul

Polycystic ovary syndrome (PCOS) is the most common endocrine condition affecting women and is associated with hyperinsulinaemia and hyperandrogenism. Obesity is present in at least 30% of cases and plays a vital role in the development and maintenance of PCOS as well as affecting the severity of the clinical and endocrine features. Significant improvements in symptoms of androgen excess and ovulatory function are seen with even a modest weight loss of 5% in women with PCOS. M...

ea0050oc6.6 | Bone, Calcium and Neoplasia | SFEBES2017

Calcium-sensing receptor (CaSR) mutations in hypercalcaemic and hypocalcaemic patients cluster at the extracellular dimer interface

Olesen Mie K , Gorvin Caroline M , Thakker Rajesh V , Hannan Fadil M

Loss- and gain-of-function mutations of the calcium-sensing receptor (CaSR) cause familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemia (ADH), respectively. The CaSR is a homodimeric receptor that has a 612 amino acid extracellular domain (ECD), which binds extracellular calcium (Ca2+e) and mediates dimer interactions upon ligand binding. The ECD consists of lobes 1 and 2, and a cysteine-rich domain (CRD). To elucidate the struc...